Cas:218776-92-2 4-(2-fluorophenyl)cyclohexan-1-one manufacturer & supplier

We serve Chemical Name:4-(2-fluorophenyl)cyclohexan-1-one CAS:218776-92-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-(2-fluorophenyl)cyclohexan-1-one

Chemical Name:4-(2-fluorophenyl)cyclohexan-1-one
CAS.NO:218776-92-2
Synonyms:4-(2-fluorophenyl)cyclohexan-1-one
Molecular Formula:C12H13FO
Molecular Weight:192.22900
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:17.07000
Exact Mass:192.09500
LogP:3.05240

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-(2-fluorophenyl)cyclohexan-1-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(2-fluorophenyl)cyclohexan-1-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(2-fluorophenyl)cyclohexan-1-one Use and application,4-(2-fluorophenyl)cyclohexan-1-one technical grade,usp/ep/jp grade.


Related News: From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend. 4-(2-fluorophenyl)cyclohexan-1-one manufacturer That impacts airlines’ business, making it less financially attractive for them to fly those routes to China. 4-(2-fluorophenyl)cyclohexan-1-one supplier As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 4-(2-fluorophenyl)cyclohexan-1-one vendor As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 4-(2-fluorophenyl)cyclohexan-1-one factory If the government does not close the border and heed their other demands by 9 p.m., union members handling emergency services would also strike, the union said.